Waltham, Massachusetts, USA, April 6, 2026
Health Canada Approval Marks Key Clinical Milestone
In a significant development for cardiovascular gene therapy, Affinia Therapeutics has received Health Canada approval to initiate the UPBEAT© Phase 1/2 clinical trial evaluating AFTX-201, a potential best-in-class gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM). This rare and severe genetic condition is characterized by progressive heart failure and high mortality, with no currently approved therapies addressing its underlying cause.
The approval follows recent regulatory momentum, including U.S. FDA Investigational New Drug (IND) clearance and Fast Track designation, as well as Orphan Drug designation from the European Medicines Agency, highlighting the therapy’s potential to address a critical unmet medical need. The UPBEAT trial will be conducted across multiple sites in the United States and Canada, focusing on evaluating safety, tolerability, pharmacodynamics, and preliminary efficacy in patients with genetically confirmed BAG3 DCM.
Innovative Gene Therapy Targets Root Cause of Disease
AFTX-201 represents a next-generation adeno-associated virus (AAV)-based gene therapy, designed to deliver a functional BAG3 gene directly to cardiac cells, thereby addressing the genetic root cause of the disease. The therapy utilizes Affinia’s proprietary capsid technology, engineered for efficient cardiac transduction at doses 5–10 times lower than conventional gene therapies, significantly improving its safety and delivery profile. Preclinical studies have demonstrated that AFTX-201 can restore BAG3 protein expression and fully recover cardiac function, providing strong scientific rationale for its clinical advancement.
Advertisement
Administered as a single intravenous infusion, the therapy offers the potential for a one-time, disease-modifying treatment, a major advancement over existing therapies that primarily manage symptoms rather than halt disease progression. With approximately 70,000 patients affected globally, BAG3 DCM represents a substantial opportunity for transformative precision medicine interventions in cardiology.
UPBEAT Trial Design and Clinical Strategy
The UPBEAT© trial is structured as a multicenter, open-label Phase 1/2 study, incorporating both dose-escalation and dose-expansion phases to identify optimal dosing while ensuring patient safety. The primary endpoint focuses on safety and tolerability over 52 weeks, while secondary and exploratory endpoints include biomarker changes, cardiac function improvement, and clinical outcomes. The study design incorporates rigorous safety monitoring protocols, including centralized data review and oversight by an independent Data Safety Monitoring Board, ensuring robust evaluation standards.
Importantly, preclinical data guiding dose selection have shown complete normalization of heart ejection fraction, indicating strong translational potential. The trial will enroll adult patients aged 18–55 years with confirmed BAG3 mutations, aiming to generate early clinical evidence supporting AFTX-201’s disease-modifying capabilities.
Transforming Treatment Landscape for Genetic Heart Disease
The advancement of AFTX-201 into clinical trials represents a broader shift toward genetic and precision-based therapies in cardiovascular medicine, an area historically dominated by symptomatic treatments. BAG3 DCM is a devastating inherited disorder, often leading to early-onset heart failure and the need for heart transplantation in up to 25% of patients, underscoring the urgent need for innovative solutions. By directly correcting the underlying genetic defect, AFTX-201 has the potential to redefine treatment paradigms and significantly improve patient outcomes.
The therapy’s low-dose efficiency, targeted delivery, and one-time administration position it as a highly differentiated candidate in the rapidly evolving field of gene therapy. As clinical data emerge from the UPBEAT trial, the global medical community will closely monitor its impact, particularly in establishing new standards for treating inherited cardiovascular diseases.
Source: Affinia Therapeutics press release
